Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis

The Journal of Rheumatology
Jean-Pierre DevogelaerKelly Krohn

Abstract

This post-hoc analysis studied the effect of baseline glucocorticoid dose on the 18-month bone mineral density (BMD) response to teriparatide 20 microg/day or alendronate 10 mg/day in 387 patients with glucocorticoid-induced osteoporosis (GIO) from a randomized, double-blind trial. Lumbar spine (LS), femoral neck (FN), and total hip (TH) BMD were measured at baseline and 18 months. Mean baseline glucocorticoid dose was categorized as low (< or = 5 mg/day), medium (> 5 and < 15 mg/day), or high (> or = 15 mg/day). Baseline LS, FN, and TH BMD were similar between groups, and between glucocorticoid dose categories within each group. LS BMD increases at the low, medium, and high glucocorticoid doses were 8.1%, 6.6%, and 4.6%, respectively, with teriparatide, and 3.6%, 2.8%, and 2.3% with alendronate. Analyzed as a continuous variable, higher glucocorticoid doses had a negative, but non-significant, effect on the percentage increase in LS BMD in both groups. Glucocorticoid dose did not significantly affect FN or TH BMD increases in either group. Across the 3 glucocorticoid dose categories, the overall LS BMD increases were different for both treatments combined (p = 0.033), but the relative differences between the treatment groups w...Continue Reading

References

Aug 17, 1999·The Journal of Clinical Investigation·R L JilkaS C Manolagas
May 10, 2000·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·N E LaneC D Arnaud
Jun 7, 2000·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·T P Van StaaC Cooper
Aug 6, 2000·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·R EastellR G Russell
Jul 5, 2003·The Journal of Clinical Endocrinology and Metabolism·Bronwyn A L CrawfordDavid J Handelsman
Feb 24, 2006·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Nancy E LaneLynda F Bonewald
May 9, 2006·Trends in Endocrinology and Metabolism : TEM·Gherardo MazziottiAndrea Giustina
Jun 2, 2006·Arthritis and Rheumatism·Jeffrey R CurtisKenneth G Saag
Sep 14, 2006·Calcified Tissue International·T P van Staa
Feb 10, 2007·Rheumatic Diseases Clinics of North America·Jean-Pierre Devogelaer
Jun 15, 2007·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·E CanalisJ P Bilezikian
Sep 1, 2007·The New England Journal of Medicine·Ernesto CanalisJohn P Bilezikian
Nov 16, 2007·The New England Journal of Medicine·Kenneth G SaagRobert Marcus
Dec 7, 2007·Annals of the New York Academy of Sciences·R Graham G RussellFrank H Ebetino
Mar 20, 2008·Current Opinion in Rheumatology·Allyson K McDonoughKenneth G Saag

❮ Previous
Next ❯

Citations

Mar 14, 2014·The Lancet. Diabetes & Endocrinology·Markus J SeibelHong Zhou
Jul 8, 2011·The New England Journal of Medicine·Robert S Weinstein
Mar 7, 2014·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·J H KregeP D Miller
Aug 11, 2012·Calcified Tissue International·R RizzoliJ Y Reginster
Apr 29, 2010·Current Osteoporosis Reports·Robert A Adler
Jun 22, 2010·Current Osteoporosis Reports·Jean-Pierre DevogelaerDaniel H Manicourt
Oct 12, 2013·Current Osteoporosis Reports·Swamy R Venuturupalli, Wendy Sacks
Dec 12, 2012·Archives of Osteoporosis·S LekamwasamUNKNOWN Joint IOF–ECTS GIO Guidelines Working Group
Sep 20, 2015·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·W YaoN E Lane
Aug 11, 2012·Endocrinology and Metabolism Clinics of North America·Robert S Weinstein
Apr 13, 2012·Cancer Treatment Reviews·Vito LongoFranco Silvestris
Oct 26, 2011·Rheumatic Diseases Clinics of North America·Jean-Pierre DevogelaerDaniel Manicourt
Feb 1, 2011·Arthritis and Rheumatism·Steven L TeitelbaumKenneth G Saag
Nov 12, 2014·Nature Reviews. Rheumatology·René Rizzoli, Emmanuel Biver
Aug 26, 2003·Mayo Clinic Proceedings·Robert A AdlerValentina I Petkov
Jul 10, 2018·The Journal of Clinical Endocrinology and Metabolism·Yi LiuEmily M Stein
May 17, 2011·PM & R : the Journal of Injury, Function, and Rehabilitation·Raj Mitra
Jul 3, 2018·Clinical Reviews in Bone and Mineral Metabolism·Amy Y SatoTeresita Bellido
Jul 12, 2012·Nature Reviews. Rheumatology·Karen Walker-Bone
Feb 1, 2020·Expert Opinion on Pharmacotherapy·Iacopo ChiodiniLuigi Gennari
Apr 15, 2020·Nature Reviews. Endocrinology·Pojchong Chotiyarnwong, Eugene V McCloskey
Jun 26, 2020·Expert Review of Endocrinology & Metabolism·Iacopo ChiodiniLuigi Gennari
Feb 26, 2019·Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·G Adami, K G Saag

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.